AGIO vs AZN

AGIO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates poor operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite strong revenue growth of 86.1% YoY, the company reports a 0.00% profit margin, negative operating margin of -608.89%, and negative ROE of -30.20%, signaling deep operational inefficiencies. Insider selling activity totaling $2.06M over six months, with multiple officer sales, underscores lack of confidence from within the organization. The stock trades at a premium valuation (Price/Sales of 30.20) with no earnings or cash flow support, and its 52-week high is 65% above current levels, indicating overvaluation relative to fundamentals.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.